The malaria and arthritis drug much-touted by President Donald Trump, hydroxychloroquine, is getting its chance under the microscope now, with the beginning of a clinical trial by the National Institutes of Health to determine its potential as a COVID-19 therapy. Testers hope the drug could have potential with adults hospitalized by the pandemic. The trial’s first participants are being pulled from Tennessee, to be enrolled at the Vanderbilt University Medical Center in Nashville, Tennessee. For the more than 500 adults expected to be enrolled, the test will be blind, placebo-controlled and randomized. It will be run by the Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network.